Neuren Pharmaceuticals

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Apr 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

13.7%

2.3%

13.7%

2.3%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

AU$24.5122.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 01 May 25

Fair value Increased 0.30%

AnalystConsensusTarget Fair Value

AU$24.51

22.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-2.43%

Pharma revenue growth rate

0.65%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.67%

Calculation

AU$228.41m

Earnings '28

15.29x

PE Ratio '28

AU$3.49b

Market Cap '28

AU$3.49b

Market Cap '28

117.22m

No. shares '28

AU$29.79

Share Price '28

AU$29.79 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$24.68

Fair Value '25